CoChat
Sign Up
Cited by 206

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

Romagnuolo, Rocco, Scipione, Corey A., Boffa, Michael B., Marcovina, Santica M., Seidah, Nabil G., Koschinsky, Marlys L.·2015·Journal of Biological Chemistry
DOI 10.1074/jbc.m114.611988
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m114.611988

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 59

  1. Boffa, 2013, Update on lipoprotein(a) as a cardiovascular risk factor and mediator, Curr. Atheroscler. Rep., 15, 360, 10.1007/s11883-013-0360-6 · DOI
  2. Tsimikas, 2012, Lipoprotein(a) as a potential causal genetic risk factor of CVD: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies, J. Am. Coll. Cardiol., 60, 716, 10.1016/j.jacc.2012.04.038 · DOI
  3. Gabel, 1995, Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a), Biochemistry., 34, 15777, 10.1021/bi00048a023 · DOI
  4. Koschinsky, 1993, Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100, J. Biol. Chem., 268, 19819, 10.1016/S0021-9258(19)36587-1 · DOI
  5. Becker, 2004, Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6–8 to lipoprotein(a) assembly, J. Biol. Chem., 279, 2679, 10.1074/jbc.M309414200 · DOI
  6. Hancock, 2003, Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces, J. Biol. Chem., 278, 23260, 10.1074/jbc.M302780200 · DOI
  7. Marcovina, 1996, Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans, J. Lipid Res., 37, 2569, 10.1016/S0022-2275(20)37461-7 · DOI
  8. Rader, 1994, The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate, J. Clin. Invest., 93, 2758, 10.1172/JCI117292 · DOI
  9. White, 1997, Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum, J. Biol. Chem., 272, 5048, 10.1074/jbc.272.8.5048 · DOI
  10. Boerwinkle, 1992, Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations, J. Clin. Invest., 90, 52, 10.1172/JCI115855 · DOI
  11. Tam, 1996, Interaction of a recombinant form of apolipoprotein(a) with human fibroblasts and with the human hepatoma cell line HepG2, J. Lipid Res., 37, 518, 10.1016/S0022-2275(20)37595-7 · DOI · Paper page
  12. Floren, 1981, Uptake of Lp(a) lipoprotein by cultured fibroblasts, Biochem. Biophys. Res. Commun., 102, 636, 10.1016/S0006-291X(81)80179-9 · DOI · Paper page
  13. Havekes, 1981, Binding of Lp(a) to the low density lipoprotein receptor of human fibroblasts, FEBS Lett., 132, 169, 10.1016/0014-5793(81)81153-2 · DOI
  14. Krempler, 1983, Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man, J. Clin. Invest., 71, 1431, 10.1172/JCI110896 · DOI · Paper page
  15. Argraves, 1997, The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor, J. Clin. Invest., 100, 2170, 10.1172/JCI119753 · DOI · Paper page
  16. März, 1993, Heterogeneous lipoprotein(a) isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/α 2-macroglobulin receptor, FEBS Lett., 325, 271, 10.1016/0014-5793(93)81087-G · DOI · Paper page
  17. Niemeier, 1999, Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro, Arterioscler. Thromb. Vasc. Biol., 19, 552, 10.1161/01.ATV.19.3.552 · DOI
  18. Yang, 2013, Scavenger receptor-BI is a receptor for lipoprotein(a), J. Lipid Res., 54, 2450, 10.1194/jlr.M038877 · DOI · Paper page
  19. Hofmann, 1990, Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice, J. Clin. Invest., 85, 1542, 10.1172/JCI114602 · DOI · Paper page
  20. Alonso, 2014, Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation, J. Am. Coll. Cardiol., 63, 1982, 10.1016/j.jacc.2014.01.063 · DOI · Paper page
  21. Kraft, 2000, Lipoprotein(a) in homozygous familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 20, 522, 10.1161/01.ATV.20.2.522 · DOI · Paper page
  22. Cain, 2005, Lipoprotein(a) is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein(a), J. Lipid Res., 46, 2681, 10.1194/jlr.M500249-JLR200 · DOI · Paper page
  23. Rader, 1995, The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans, J. Clin. Invest., 95, 1403, 10.1172/JCI117794 · DOI · Paper page
  24. McKenney, 2012, Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy, J. Am. Coll. Cardiol., 59, 2344, 10.1016/j.jacc.2012.03.007 · DOI
  25. Roth, 2012, Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia, N. Engl. J. Med., 367, 1891, 10.1056/NEJMoa1201832 · DOI
  26. Desai, 2013, Circulation., 128, 962, 10.1161/CIRCULATIONAHA.113.001969 · DOI
  27. Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials, J. Am. Coll. Cardiol., 63, 1278, 10.1016/j.jacc.2014.01.006 · DOI
  28. Stein, 2014, Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials, Eur. Heart J., 35, 2249, 10.1093/eurheartj/ehu085 · DOI · Paper page
  29. Gaudet, 2014, Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials), Am. J. Cardiol., 114, 711, 10.1016/j.amjcard.2014.05.060 · DOI
  30. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  31. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. U.S.A., 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  32. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  33. Abifadel, 2009, Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease, Hum. Mutat., 30, 520, 10.1002/humu.20882 · DOI
  34. Canuel, 2013, Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1), PLoS One., 8, e64145, 10.1371/journal.pone.0064145 · DOI · Paper page
  35. Frykman, 1995, Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor, Proc. Natl. Acad. Sci. U.S.A., 92, 8453, 10.1073/pnas.92.18.8453 · DOI · Paper page
  36. Marcovina, 1995, Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a), Clin. Chem., 41, 246, 10.1093/clinchem/41.2.246 · DOI
  37. Romagnuolo, 2014, Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a), J. Lipid Res., 55, 625, 10.1194/jlr.M036566 · DOI
  38. Poirier, 2009, Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route, J. Biol. Chem., 284, 28856, 10.1074/jbc.M109.037085 · DOI · Paper page
  39. Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  40. Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. U.S.A., 105, 1820, 10.1073/pnas.0712064105 · DOI · Paper page
  41. Miles, 1995, Interaction of Lp(a) with plasminogen binding sites on cells, Thromb. Haemost., 73, 458, 10.1055/s-0038-1653797 · DOI
  42. Nassoury, 2007, The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR, Traffic., 8, 718, 10.1111/j.1600-0854.2007.00562.x · DOI · Paper page
  43. Wang, 2012, Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR, J. Lipid Res., 53, 1932, 10.1194/jlr.M028563 · DOI · Paper page
  44. Ernst, 1995, Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32–36 of human apolipoprotein(a), J. Biol. Chem., 270, 6227, 10.1074/jbc.270.11.6227 · DOI
  45. Garcia, 2001, Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein, Science., 292, 1394, 10.1126/science.1060458 · DOI · Paper page
  46. Nguyen, 2006, Binding characteristics of a panel of monoclonal antibodies against the ligand binding domain of the human LDLr, J. Lipid Res., 47, 1399, 10.1194/jlr.M600130-JLR200 · DOI
  47. Becker, 2003, A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation, J. Biol. Chem., 278, 14074, 10.1074/jbc.M212855200 · DOI
  48. Barrett, 1982, l-trans-Epoxysuccinyl-leucylamide(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L, Biochem. J., 201, 189, 10.1042/bj2010189 · DOI
  49. Fenteany, 1998, Lactacystin, proteasome function, and cell fate, J. Biol. Chem., 273, 8545, 10.1074/jbc.273.15.8545 · DOI
  50. Dröse, 1993, Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases, Biochemistry., 32, 3902, 10.1021/bi00066a008 · DOI
  51. Tziomalos, 2009, Lipoprotein a: where are we now?, Curr. Opin. Cardiol., 24, 351, 10.1097/HCO.0b013e32832ac21a · DOI
  52. Gonbert, 2002, Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk, Atherosclerosis., 164, 305, 10.1016/S0021-9150(02)00072-2 · DOI
  53. van Wissen, 2003, Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia, Heart., 89, 893, 10.1136/heart.89.8.893 · DOI · Paper page
  54. Bea, 2014, (Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia.), Clin. Investig. Arterioscler., 26, 176
  55. Soutar, 1991, Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the Pro664 → Leu mutation in the LDL receptor gene, J. Clin. Invest., 88, 483, 10.1172/JCI115329 · DOI
  56. Ghiselli, 1992, Plasma lipoprotein(a) concentration in familial hypercholesterolemic patients without coronary artery disease, Metabolism., 41, 833, 10.1016/0026-0495(92)90163-5 · DOI
  57. Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J. Clin. Invest., 116, 2995, 10.1172/JCI29383 · DOI · Paper page
  58. Strøm, 2010, Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain, Mol. Genet. Metab., 101, 76, 10.1016/j.ymgme.2010.05.003 · DOI · Paper page
  59. Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Romagnuolo, R., Scipione, C. A., Boffa, M. B., Marcovina, S. M., Seidah, N. G., & Koschinsky, M. L.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2015-05
Volume
290
Issue
18
Pages
11649-11662
ISSN
0021-9258
DOI
10.1074/jbc.m114.611988
Cited by
206
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review